NRX Pharmaceuticals, Inc. (NRXP): auditor change — NRx Pharmaceuticals dismisses KPMG as auditor, appoints Salberg & Company

NRX Pharmaceuticals, Inc.

Dismissed KPMG effective Nov 15, 2023; no disagreements in past two fiscal years.
KPMG's reports for FY2021 and FY2022 included a going concern qualification.
Material weakness in segregation of duties identified for 2021 through Q3 2022; remediated as of Dec 31, 2022.
Engaged Salberg & Company as new independent auditor for FY2023, effective Nov 17, 2023.
No prior consultations with Salberg on any accounting or auditing matters.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

NRX Pharmaceuticals, Inc. engaged Salberg & Company, P.A. as its auditor.

Action: engagement
Auditor: Salberg & Company, P.A.

Exact text from the filing

On November 17, 2023, the Board engaged Salberg & Company, P.A. (“Salberg”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

NRX Pharmaceuticals, Inc. dismissed KPMG LLP as its auditor.

Action: dismissal
Auditor: KPMG LLP
Successor: Salberg & Company, P.A.

Exact text from the filing

On November 15, 2023, the Board of Directors (the “Board”) of the Company approved the dismissal of KPMG as the Company’s independent registered public accounting firm, effective immediately.

View on SEC.gov

Browse all auditor changes →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-120777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.